Jasmohan S Bajaj1, Jacqueline G OʼLeary2,3, Puneeta Tandon4, Florence Wong5, Guadalupe Garcia-Tsao6, Patrick S Kamath7, Scott W Biggins8,9, Jennifer C Lai10, Hugo E Vargas11, Benedict Maliakkal12,13, Michael B Fallon14,15, Paul J Thuluvath16, Ram M Subramanian17, Leroy R Thacker1, K Rajender Reddy18. 1. Virginia Commonwealth University and McGuire Virginia Medical Center, Richmond, Virginia, USA. 2. Baylor University Medical Center, Dallas, Texas, USA. 3. Dallas VA Medical Center, Dallas, Texas, USA. 4. University of Alberta, Edmonton, Alberta, Canada. 5. University of Toronto, Toronto, Ontario, Canada. 6. Yale University School of Medicine New Haven, Connecticut, USA. 7. Mayo Clinic School of Medicine, Rochester, Minnesota, USA. 8. University of Colorado, Denver, Colorado, USA. 9. University of Washington, Seattle, Washington, USA. 10. University of California, San Francisco, California, USA. 11. Mayo Clinic School of Medicine, Scottsdale, Arizona, USA. 12. University of Rochester, Rochester, New York, USA. 13. University of Tennessee, Memphis, Tennessee, USA. 14. University of Texas, Houston, Texas, USA. 15. University of Arizona, Phoenix, Arizona, USA. 16. Mercy Medical Center, Baltimore, Maryland, USA. 17. Emory University Medical Center, Atlanta, Georgia, USA. 18. University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
OBJECTIVES: Nosocomial infections (NIs) can be a major cause of morbidity and mortality in cirrhosis. This study aims to define the determinants of NI development and its impact on 30-day outcomes among hospitalized patients with cirrhosis. METHODS: North American Consortium for the Study of End-Stage Liver Disease enrolled patients with cirrhosis who were admitted nonelectively. Admission variables and 30-day outcomes were compared between patients with and without NI. These were also compared based on whether there was an isolated admission infection, NI, or both. Models were created for NI development using admission variables and for 30-day mortality. RESULTS: The study included 2,864 patients; of which, 15% (n = 436) developed NI. When comparing NI vs no NI, 1,866 patients were found to be infection free, whereas 562 had admission infections only, 228 had only NI, and 208 had both infections. At admission, patients with NI were more likely to be infected and have advanced cirrhosis. NIs were associated with higher rates of acute-on-chronic liver failure, death, and transplant regardless of admission infections. Patients with NI had higher respiratory infection, urinary tract infection, Clostridium difficile infection, fungal infections, and infection with vancomycin-resistant enterococci compared with patients without NI. Risk factors for NIs were admission infections, model for end-stage liver disease (MELD) > 20, systemic inflammatory response syndrome criteria, proton pump inhibitor, rifaximin, and lactulose use, but the regression model (sensitivity, 0.67; specificity, 0.63) was not robust. Age, alcohol etiology, admission MELD score, lactulose use, acute-on-chronic liver failure, acute kidney injury, intensive care unit, and NI increased the risk of death, whereas rifaximin decreased the risk of death. DISCUSSION: NIs are prevalent in hospitalized patients with cirrhosis and are associated with poor outcomes. Although higher MELD scores and systemic inflammatory response syndrome are associated with NI, all hospitalized patients with cirrhosis require vigilance and preventive strategies.
OBJECTIVES:Nosocomial infections (NIs) can be a major cause of morbidity and mortality in cirrhosis. This study aims to define the determinants of NI development and its impact on 30-day outcomes among hospitalized patients with cirrhosis. METHODS: North American Consortium for the Study of End-Stage Liver Disease enrolled patients with cirrhosis who were admitted nonelectively. Admission variables and 30-day outcomes were compared between patients with and without NI. These were also compared based on whether there was an isolated admission infection, NI, or both. Models were created for NI development using admission variables and for 30-day mortality. RESULTS: The study included 2,864 patients; of which, 15% (n = 436) developed NI. When comparing NI vs no NI, 1,866 patients were found to be infection free, whereas 562 had admission infections only, 228 had only NI, and 208 had both infections. At admission, patients with NI were more likely to be infected and have advanced cirrhosis. NIs were associated with higher rates of acute-on-chronic liver failure, death, and transplant regardless of admission infections. Patients with NI had higher respiratory infection, urinary tract infection, Clostridium difficileinfection, fungal infections, and infection with vancomycin-resistant enterococci compared with patients without NI. Risk factors for NIs were admission infections, model for end-stage liver disease (MELD) > 20, systemic inflammatory response syndrome criteria, proton pump inhibitor, rifaximin, and lactulose use, but the regression model (sensitivity, 0.67; specificity, 0.63) was not robust. Age, alcohol etiology, admission MELD score, lactulose use, acute-on-chronic liver failure, acute kidney injury, intensive care unit, and NI increased the risk of death, whereas rifaximin decreased the risk of death. DISCUSSION: NIs are prevalent in hospitalized patients with cirrhosis and are associated with poor outcomes. Although higher MELD scores and systemic inflammatory response syndrome are associated with NI, all hospitalized patients with cirrhosis require vigilance and preventive strategies.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jasmohan S Bajaj; Jacqueline G O'Leary; K Rajender Reddy; Florence Wong; Jody C Olson; Ram M Subramanian; Geri Brown; Nicole A Noble; Leroy R Thacker; Patrick S Kamath Journal: Hepatology Date: 2012-12 Impact factor: 17.425
Authors: Jacqueline G O'Leary; K Rajender Reddy; Florence Wong; Patrick S Kamath; Heather M Patton; Scott W Biggins; Michael B Fallon; Guadalupe Garcia-Tsao; Ram M Subramanian; Raza Malik; Leroy R Thacker; Jasmohan S Bajaj Journal: Clin Gastroenterol Hepatol Date: 2014-08-12 Impact factor: 11.382
Authors: Jasmohan S Bajaj; Douglas M Heuman; Phillip B Hylemon; Arun J Sanyal; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel B Unser; Kalyani Daita; Andmorgan R Fisher; Masoumeh Sikaroodi; Patrick M Gillevet Journal: J Hepatol Date: 2013-12-25 Impact factor: 25.083
Authors: Amirhossein Shamsaddini; Patrick M Gillevet; Chathur Acharya; Andrew Fagan; Edith Gavis; Masoumeh Sikaroodi; Sara McGeorge; Alexander Khoruts; Somaya Albhaisi; Michael Fuchs; Richard K Sterling; Jasmohan S Bajaj Journal: Gastroenterology Date: 2021-04-20 Impact factor: 33.883
Authors: Jasmohan S Bajaj; Amirhossein Shamsaddini; Andrew Fagan; Richard K Sterling; Edith Gavis; Alexander Khoruts; Michael Fuchs; Hannah Lee; Masoumeh Sikaroodi; Patrick M Gillevet Journal: Hepatol Commun Date: 2020-11-21